Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRGN-3005
- Development stage
- Phase 1
- Lead developer
- Precigen
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intraperitoneal
01
Overview
PRGN-3005 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Precigen Inc. It targets the unshed portion of Mucin 16 (MUC16) and expresses membrane-bound IL-15 (mbIL15) to enhance persistence and a kill switch for safety. It is primarily indicated for the treatment of advanced, recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
- Brand names
- UltraCAR-T
- Other names
- PRGN-3005 UltraCAR-T cellsPRGN3005 UltraCAR-T cellsPRGN 3005 UltraCAR-T cellsMUC16-targeted CAR-T cellsMUC-16-targeted CAR-T cellsMUC 16-targeted CAR-T cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)MUC16 (Mucin-16)
Beyond the preview
Go deeper on PRGN-3005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRGN-3005.